Company
Headquarters: Kusnacht, Switzerland
Employees: 10
CHF1.67 Billion
CHF as of July 1, 2025
US$2.12 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CHF201.4 M |
| EBITDA | CHF0 |
| Gross Profit TTM | CHF201.4 M |
| Profit Margin | 82.47% |
| Operating Margin | 98.53% |
| Quarterly Revenue Growth | -60.79% |
BB Biotech AG has the following listings and related stock indices.
Stock: SIX: BION
Stock: MTA: BB
Stock: OTC: BBAGF